Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients - 03/01/17
pages | 5 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objectives |
The purpose of the present study was to evaluate the prognostic value of miR-199b-5p in breast cancer patients, as well as explore its effects on breast cancer cells.
Methods |
The expression level of miR-199b-5p in breast cancer tissues and paired non-cancerous tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to evaluate the relationship between miR-199b-5p expression and clinical parameters. Besides, overall survival analysis was carried out with Kaplan-Meier curve with log rank test, and the prognostic value of miR-199b-5p in breast cancer was evaluated by cox regression model. In addition, MTT and transwell assays in vitro were used to estimate the effects of miR-199b-5p on breast cancer cells.
Results |
MiR-199b-5p was down-regulated in breast cancer tissues, compared with adjacent normal tissues (P<0.05). Moreover, its decreased level was significantly correlated with advanced TNM stage (P=0.008) and positive lymph node metastasis (P=0.013). Cell experiments suggested that miR-199b-5p could regulate proliferation and invasion of breast cancer cells. In addition, we found that breast cancer patients with low miR-199b-5p expression level had poorer overall survival than those with high level (log rank test, P=0.021). MiR-199b-5p was an independent prognostic factor for breast cancer patients (HR=2.318, 95%CI=1.086–4.949, P=0.030).
Conclusion |
Down-regulated miR-199b-5p in breast cancer patients is associated with malignant clinical characteristics. MiR-199b-5p may be a potential prognostic biomarker for breast cancer.
Le texte complet de cet article est disponible en PDF.Keywords : MiR-199b-5p, Prognosis, Breast cancer
Plan
Vol 84
P. 1189-1193 - décembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?